A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer-Reference-Cited by-同舟云学术

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer

Published:2016-06 Issue:3 Volume:157 Page:527-534
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Zhou Yijun,Ouyang Tao,Xie Yuntao,Wang Tianfeng,Fan Zhaoqing,He Yingjian,Lu Aiping,Liu Yiqiang,Li Jinfeng

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-3843-7.pdf

Reference20 articles.

1. Iqbal J, Shafi AA, Alharthi BN (2014) Neoadjuvant chemotherapy in locally advanced breast cancer. J Coll Phys Surg Pak 24(11):845–848

2. Caudle AS, Kuerer HM (2014) Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach. J Surg Oncol 110(1):32–36

3. Read RL, Flitcroft K, Snook KL, Boyle FM, Spillane AJ (2015) Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer. ANZ J Surg 85(5):315–320

4. Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, Ferrari L, Bottini A, Bruzzi P, Sormani MP (2014) Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 32(34):3883–3891

5. Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P et al (2015) Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Crit Rev Oncol Hematol 95(1):88–104

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal Adhesion Kinase Inhibitor Inhibits the Oxidative Damage Induced by Central Venous Catheter via Abolishing Focal Adhesion Kinase-Protein Kinase B Pathway Activation;BioMed Research International;2021-03-01

2. Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study;Gland Surgery;2020-08

3. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review;Cancer Medicine;2020-05-26